SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE

Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in p

Related stories